NIRSE-GAL updates
Publications
Eurosurveillance
Martinón-Torres F, Mirás-Carballal S, Durán-Parrondo C.
Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023.
The Journal of Infectious Diseases
Preparing Europe for Introduction of Immunization Against RSV: Bridging the Evidence and Policy Gap.
On the cover: RSV Immunization: From Bench to Arms. The first picture is from the immunization campaign in Galicia, Spain this winter, where they successfully immunized all their children under one year of age with spectacular results. Credit: Prof Federico Martinon-Torres and Mr Carlos Bermello. The second picture is of Prof Barney Graham, who led the discovery of the structure of the F protein that revolutionized the field of RSV vaccines. He is holding a 3D model of the structure of the F protein while getting immunized at Walgreens community pharmacy last autumn. Credit: Dr. Cynthia Turner-Graham.
The Lancet Infectious Diseases – Nirse-Gal Study Paper
Effectiveness and impact of universal prophylaxis with Nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study.
Galicia (Spain) was one of the first regions worldwide to incorporate nirsevimab for universal respiratory syncytial virus (RSV) prophylaxis in infants into its immunisation programme. The NIRSE-GAL longitudinal population-based study aimed to assess nirsevimab effectiveness in preventing hospitalisations (ie, admittance to hospital).
Conferences and congresses
